Home/Filings/4/0001144204-08-021622
4//SEC Filing

NEXMED INC 4

Accession 0001144204-08-021622

CIK 0001017491operating

Filed

Apr 9, 8:00 PM ET

Accepted

Apr 10, 5:10 PM ET

Size

6.2 KB

Accession

0001144204-08-021622

Insider Transaction Report

Form 4
Period: 2006-08-03
Westgate Mark
Vice President & CFO
Transactions
  • Award

    Stock Options

    2006-08-03+80,00080,000 total
    Exercise: $0.81Exp: 2016-08-03Common Stock (80,000 underlying)
Footnotes (2)
  • [F1]On August 3, 2006, the Company's Board of Directors approved an option grant to purchase 80,000 shares of the Company's common stock to Mr. Westgate, which was to vest in two equal installments contingent upon the filing of a New Drug Application ("NDA") for the Company's topical alprostadil-based cream treatment intended for patients with erectile dysfunction and upon the Food and Drug Administration's acceptance of the NDA for review. The Company's NDA was successfully filed on September 21, 2007 and accepted for review on November 20, 2007, and the options became fully vested on such dates. The option price is based upon the closing price of the Company's common stock at the time of the grant.
  • [F2]This option grant was not reported on a Form 4 at the time of the grant.

Documents

1 file

Issuer

NEXMED INC

CIK 0001017491

Entity typeoperating
IncorporatedNV

Related Parties

1
  • filerCIK 0001017491

Filing Metadata

Form type
4
Filed
Apr 9, 8:00 PM ET
Accepted
Apr 10, 5:10 PM ET
Size
6.2 KB